BIZENGRI Market Summary

Key Factors Driving BIZENGRI Growth

1. Expansion to a third FDA-approved indication is a major growth catalyst

BIZENGRI initially received FDA accelerated approval in December 2024 for previously treated, advanced/metastatic NRG1 fusion-positive NSCLC and pancreatic adenocarcinoma. In May 2026, FDA approved it for NRG1 fusion-positive advanced/metastatic cholangiocarcinoma, making it the first targeted therapy specifically approved for NRG1+ cholangiocarcinoma. This expands the commercial opportunity beyond the original two tumor types and provides an additional revenue stream.

2. Strong efficacy in NRG1 fusion-positive NSCLC and pancreatic cancer

The pivotal eNRGy study provides a strong clinical foundation. In 30 NRG1+ pancreatic adenocarcinoma patients, BIZENGRI produced an objective response rate (ORR) of 40%, with duration of response ranging from 3.7 to 16.6 months. In 64 NRG1+ NSCLC patients, ORR was 33%, with a median duration of response of 7.4 months. These results supported the FDA's accelerated approval and provide evidence of clinically meaningful activity in cancers with very limited targeted treatment options.

3. Particularly strong opportunity from the rarity and lack of alternatives for NRG1+ cancers

NRG1 fusions occur in <1% of solid tumors, making the population small but highly defined. Importantly, before BIZENGRI, patients with NRG1 fusion-positive NSCLC or pancreatic cancer lacked an FDA-approved systemic therapy specifically targeting this driver. The FDA described the 2024 approval as the first systemic therapy approval for NRG1 fusion-positive NSCLC and pancreatic adenocarcinoma. This gives BIZENGRI a highly differentiated position despite the relatively small biomarker-defined population.

4. Novel HER2×HER3 “Dock & Block” mechanism differentiates BIZENGRI

BIZENGRI simultaneously binds HER2 and HER3, blocking the interaction between NRG1 fusion proteins and HER3 and preventing HER2/HER3 signaling. NRG1 fusions act as oncogenic drivers by producing abnormal NRG1 proteins that activate HER3 and downstream proliferative pathways. BIZENGRI therefore directly targets the molecular mechanism driving these cancers rather than functioning as nonspecific chemotherapy. This biomarker-driven mechanism supports use across several tumor types carrying NRG1 fusions.

5. Cholangiocarcinoma data provide another meaningful expansion opportunity

The newly approved cholangiocarcinoma indication is supported by Phase II eNRGy data. Among 22 patients with NRG1 fusion-positive cholangiocarcinoma, 19 were efficacy-evaluable and ORR was 36.8%, with duration of response ranging from 2.8 to 12.9 months. The company also reported a median progression-free survival of more than nine months in this population. NRG1 fusions occur in <1% of cholangiocarcinomas, but this population has particularly high unmet need, making BIZENGRI a potentially valuable precision-oncology treatment despite the small patient pool.

BIZENGRI Recent Developments

In May 2026, Partner Therapeutics announced that the US Food and Drug Administration (FDA) has approved BIZENGRI (zenocutuzumab-zbco) for the treatment of adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. This marks the first targeted therapy approved specifically for NRG1+ cholangiocarcinoma, a molecularly defined cancer with a profound unmet need. The approval was expedited by PTx's receipt of a Commissioner's National Priority Voucher (CNPV). BIZENGRI previously received Breakthrough Therapy Designation and Orphan Drug Designation from the FDA for NRG1+ cholangiocarcinoma, reflecting the unmet need in this patient population.

“BIZENGRI Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of BIZENGRI for approved indication like Adenocarcinoma, Cholangiocarcinoma, and Non-small cell lung cancer; as well as potential indication like HER2 positive breast cancer, Prostate cancer, Solid tumours, and Cancer in the 7MM. A detailed picture of BIZENGRI’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the BIZENGRI for approved and potential indications. The BIZENGRI market report provides insights about BIZENGRI’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current BIZENGRI performance, future market assessments inclusive of the BIZENGRI market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of BIZENGRI sales forecasts, along with factors driving its market.

BIZENGRI Drug Summary

BIZENGRI is a bispecific antibody directed against HER2 and HER3, developed for the treatment of adults with advanced, unresectable, or metastatic neuregulin 1 (NRG1) fusion-positive non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma, and cholangiocarcinoma following disease progression on or after prior systemic therapy. Zenocutuzumab simultaneously binds the extracellular domains of HER2 and HER3, thereby inhibiting HER2/HER3 dimerization and blocking NRG1 binding to HER3, which suppresses downstream signaling through the PI3K-AKT-mTOR pathway and can also promote antibody-dependent cellular cytotoxicity. BIZENGRI is administered as an intravenous infusion at a recommended dose of 750 mg every two weeks until disease progression or unacceptable toxicity. The drug received accelerated FDA approval in December 2024 for NRG1 fusion-positive NSCLC and pancreatic adenocarcinoma and was subsequently approved in May 2026 for NRG1 fusion-positive cholangiocarcinoma. In the pivotal eNRGy study, BIZENGRI demonstrated overall response rates of 33% in NRG1 fusion-positive NSCLC and 40% in pancreatic adenocarcinoma, supporting its role as a targeted treatment option for these rare molecularly defined cancers. The report provides BIZENGRI’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the BIZENGRI Market Report

The report provides insights into:

• A comprehensive product overview including the BIZENGRI MoA, description, dosage and administration, research and development activities in approved indications like Adenocarcinoma, Cholangiocarcinoma, and Non-small cell lung cancer; as well as potential indication like HER2 positive breast cancer, Prostate cancer, Solid tumours, and Cancer.
• Elaborated details on BIZENGRI regulatory milestones and other development activities have been provided in BIZENGRI market report.
• The report also highlights BIZENGRI‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The BIZENGRI market report also covers the patents information, generic entry and impact on cost cut.
• The BIZENGRI market report contains current and forecasted BIZENGRI sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The BIZENGRI market report also features the SWOT analysis with analyst views for BIZENGRI in approved and potential indications.

Methodology

The BIZENGRI market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

BIZENGRI Analytical Perspective by DelveInsight

• In-depth BIZENGRI Market Assessment

This BIZENGRI sales market forecast report provides a detailed market assessment of BIZENGRI for approved indication like Adenocarcinoma, Cholangiocarcinoma, and Non-small cell lung cancer; as well as potential indication like HER2 positive breast cancer, Prostate cancer, Solid tumours, and Cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted BIZENGRI sales data uptil 2034.

• BIZENGRI Clinical Assessment

The BIZENGRI market report provides the clinical trials information of BIZENGRI for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

BIZENGRI Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

BIZENGRI Market Potential & Revenue Forecast

• Projected market size for the BIZENGRI and its key indications
• Estimated BIZENGRI sales potential (BIZENGRI peak sales forecasts)
• BIZENGRI Pricing strategies and reimbursement landscape

BIZENGRI Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• BIZENGRI Market positioning compared to existing treatments
• BIZENGRI Strengths & weaknesses relative to competitors

BIZENGRI Regulatory & Commercial Milestones

• BIZENGRI Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

BIZENGRI Clinical Differentiation

• BIZENGRI Efficacy & safety advantages over existing drugs
• BIZENGRI Unique selling points

BIZENGRI Market Report Highlights

• In the coming years, the BIZENGRI market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The BIZENGRI companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence BIZENGRI’s dominance.
• Other emerging products for Adenocarcinoma, Cholangiocarcinoma, and Non-small cell lung cancer; as well as potential indication like HER2 positive breast cancer, Prostate cancer, Solid tumours, and Cancer are expected to give tough market competition to BIZENGRI and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of BIZENGRI in approved and potential indications.
• Analyse BIZENGRI cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted BIZENGRI sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of BIZENGRI in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of BIZENGRI? How strong is BIZENGRI’s clinical and commercial performance?
• What is BIZENGRI’s clinical trial status in each individual indications such as Adenocarcinoma, Cholangiocarcinoma, and Non-small cell lung cancer; as well as potential indication like HER2 positive breast cancer, Prostate cancer, Solid tumours, and Cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the BIZENGRI Manufacturers?
• What are the key designations that have been granted to BIZENGRI for approved and potential indications? How are they going to impact BIZENGRI’s penetration in various geographies?
• What is the current and forecasted BIZENGRI market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of BIZENGRI in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to BIZENGRI for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is BIZENGRI? What is the duration of therapy and what are the geographical variations in cost per patient?